Semaglutide

CAS 910463-68-2 61 current recordsPeptide

Who holds supplier records for Semaglutide? 61 organisations hold a current record for Semaglutide: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: China (35), India (7), Belgium (1), United States (1) and 1 other country (1); not recorded for 16.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Semaglutide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/semaglutide

Reading the evidence

  • 61 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in China

    35 of the 45 current records with a recorded country list China. Organisation country is not necessarily the manufacturing site.

  • 12 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Semaglutide expires 17 Feb 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (61)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Semaglutide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Semaglutide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (28 listed products contain Semaglutide). The latest listed patent expires 17 Feb 2041. The latest listed exclusivity runs to 19 Mar 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and chronic weight management. It stimulates insulin secretion and signals to the brain to reduce appetite and caloric intake.

Chemical identity

IUPAC name
18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
Canonical SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
InChIKey
DLSWIYLPEUIQAV-CCUURXOWSA-N
Synonyms
cagrisema component semaglutide, nn-9535, nn1535 icosema component semaglutide, nn1535 laisema component semaglutide, nn9535, nnc 0113-0217, nnc-0113-0217, ozempic, rybelsus, wegovy

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
GLP-1 Receptor Agonist
Mechanism of action
Glucagon-like Peptide-1 (GLP-1) Agonists
Chemical structure
Glucagon-Like Peptide 1

Therapeutic areas

DiabetesWeight ManagementMetabolic Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Semaglutide?

61 organisations hold an active US FDA Type II Drug Master File or a CEP for Semaglutide: FUJIAN GENOHOPE BIOTECH LTD (China), SHENZHEN JYMED TECHNOLOGY CO LTD (China), ZHEJIANG PEPTITES BIOTECH CO LTD (China), Hybio Pharmaceutical Co., Ltd. (China), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD (China), Polypeptide (Belgium), Yangzhou Aurisco Pharmaceutical Co.,Ltd. (China) and ALP PHARM BEIJING CO LTD, and 53 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Semaglutide Drug Master Files are active?

FUJIAN GENOHOPE BIOTECH LTD (DMF 39522, 40957), SHENZHEN JYMED TECHNOLOGY CO LTD (DMF 41170, 36009), ZHEJIANG PEPTITES BIOTECH CO LTD (DMF 42288, 35712), Hybio Pharmaceutical Co., Ltd. (DMF 44328, 40319), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD (DMF 43275, 42796), Polypeptide (DMF 36101, 38177), Yangzhou Aurisco Pharmaceutical Co.,Ltd. (DMF 38479, 42525) and ALP PHARM BEIJING CO LTD (DMF 35875) and 53 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Semaglutide?

Yes. The latest patent listed for an approved US product containing Semaglutide expires 17 Feb 2041, across 28 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Semaglutide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Semaglutide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.